Mark Bunnage is a senior vice president at Vertex Pharmaceuticals. He studied chemistry at the University of Durham and conducted postgraduate research with Professor SG Davies at the University of Oxford. Mark then moved to The Scripps Research Institute in La Jolla, USA to work with Professor KC Nicolaou as a NATO postdoctoral fellow. In 1996, Mark joined Pfizer in the UK as a medicinal chemist, and in 2010, he became executive director, head of Medicinal Chemistry, Sandwich Laboratories. In April 2011, Mark was appointed vice president, worldwide Medicinal Chemistry, and relocated to Cambridge, MA. In that role, Mark was responsible for small-molecule drug discovery support across two Pfizer Research Units (Inflammation & Immunology, Rare Diseases) and acted as chemistry lead for Pfizer's CTI (Centers for Therapeutic Innovation) network. Mark has broad interests in drug discovery, is an author or inventor on over 50 publications and patents, is editor of the book ‘New Frontiers in Chemical Biology’ and serves on the board of directors for the SGC. Mark is also a visiting professor in Chemistry at the University of Oxford.